



## Multi-epitope Vaccines against Neglected, Emerging, and Re-emerging Global Diseases

Guest Editor:

### Dr. Cerrone Cabanos

1. Graduate School of Agriculture,  
Kyoto University, Kyoto, Japan  
2. Institute for Liberal Arts and  
Sciences, Kyoto University,  
Kyoto, Japan

Deadline for manuscript  
submissions:

**closed (30 June 2024)**

### Message from the Guest Editor

Neglected Global Diseases are infectious diseases and other conditions that cause physical and cognitive impairments, including maternal, infant and child health conditions; neglected tropical diseases; as well as malaria, tuberculosis, and HIV/AIDS. As climate change pushes the natural selection of pathogens and their vectors and natural reservoirs, the risk of these neglected diseases emerging within a larger global population poses an even greater threat. Vaccination is still viewed as the most effective method of preventing these infectious diseases by inducing protective immunity.

This Special Issue invites articles and reviews involving multi-epitope vaccine design against neglected, emerging, and re-emerging global diseases, as well as methodologies, novel evaluation, and prediction tools for vaccine design improvement. This issue also welcomes works involving the recombinant production and in vitro and/or in vivo validation of these chimeric vaccines.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)